Lyubov Slashcheva, Rick Rader, MD, and Stephen B. Sulkes, MD
Designation of people with intellectual and developmental disabilities as a medically underserved population would not solve problems of access to care.
AMA J Ethics. 2016;18(4):422-429. doi:
10.1001/journalofethics.2016.18.4.pfor1-1604.
This month on Ethics Talk, Dr Sheryl Fleisch discusses strategies for delivering health services to people experiencing homelessness, including street psychiatry.
Clinicians with obligations to patients and to organizations often assess patients in law enforcement for both therapeutic and nontherapeutic purposes.
AMA J Ethics. 2022;24(2):E111-119. doi:
10.1001/amajethics.2022.111.
Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
Health care reform expanded health insurance to millions, but current community benefit policies must be used by organizations hoping to address social determinants.
AMA J Ethics. 2019;21(3):E248-258. doi:
10.1001/amajethics.2019.248.